Cover Image
市場調查報告書

遺傳基因檢驗的全球市場

Genetic Testing

出版商 Global Industry Analysts, Inc. 商品編碼 236763
出版日期 內容資訊 英文 343 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
遺傳基因檢驗的全球市場 Genetic Testing
出版日期: 2015年05月01日 內容資訊: 英文 343 Pages
簡介

本報告以遺傳基因檢驗的全球市場為焦點,依產品市場區隔 (產前及新生兒遺傳基因檢驗藥理基因學檢驗,預測診斷) 及地區 (美國,加拿大,日本,歐洲,亞太地區,其他) 別檢驗·預測2014-2020年這段期間之交易金額,並彙整過去7年的市場過程分析和大小86家參與企業公司的簡介等目前競爭環境相關的調查資訊。

第1章 簡介,調查方法,產品定義

  • 調查的可靠性和報告的限制
  • 免責聲明
  • 資料的解釋和報告作成層級
    • 定量技術與分析
  • 產品的定義和調查範圍
    • 產前及新生兒遺傳基因檢驗藥理遺傳基因檢驗,藥理基因學檢驗
    • 預測診斷

第2章 摘要整理

  • 全球市場概要
    • 概要基礎知識
    • 全球10大遺傳基因障礙
    • 遺傳基因檢驗-宣告新時代的到來
    • 穩固定制醫療地位的遺傳基因檢驗
    • 全球人口膨脹帶來的成長機會擴大
    • 因人口高齡化而加速的遺傳基因檢驗市場
    • 因醫療支出的提高促使需求大幅增加
    • 遺傳基因檢驗-正在急速發展對體外診斷(IVD)市場而言不可或缺的因素
    • 遺傳基因檢驗-分子診斷市場的急速成長市場區隔
    • 遺傳檢驗的進步相關之生物標記的發現
    • 美國食品藥物管理局核準的癌症生物標記一覽
  • 市場區隔考察
    • 興起的產前檢查
    • 各現象,表現症狀,盛行率別之遺傳基因障礙一覽
    • 產前檢查-改變妊娠治療世界之物
    • 產前檢查-基本的概要
    • 可利用的產前篩檢及診斷法的症狀別一覽
    • 傳統的產前診斷技術-伴隨危險性的工作
    • 激化的胎兒染色體檢驗(NIPD)市場上的競爭
    • 排除傳統診斷法的危險性和不確定性之胎兒染色體檢驗
    • 對胎兒染色體檢驗法的異議-普及的一大難關
    • 產前檢查的優點和阻礙普及的倫理問題
    • 優點超越潛在性障礙的胎兒染色體檢驗
    • 影響胎兒染色體檢驗普及的主要係數
    • 胎兒染色體檢驗可望用途的多樣性
    • 預測診斷
    • 穩定擴大的乳癌遺傳基因檢驗市場
    • 多元化的遺傳學-乳癌檢驗中不容置疑的第一領域
    • 例行性臨床試驗 vs.預測遺傳基因檢驗
    • CDD發生數·盛行率的擴大-主要成長推動要素
    • 預測診斷不可或缺的新型生物標記的發現
    • 未解決的問題 一以遺傳基因疾病為對象的遺傳基因診斷和檢驗廣泛實施之妨礙
    • 遺傳基因諮詢師的不足-對預測遺傳基因測試市場而言的一大障礙
    • 藥理基因學的發展為遺傳基因檢驗市場成長帶來吉兆
  • 市場趨勢
    • 門診病人(Direct-to-Consumer)遺傳基因檢驗-遺傳基因檢驗市場上主要趨勢
    • 製作新企業的平台
    • 門診病人遺傳基因檢驗經營者的經營模式
    • 擴大門診病人遺傳基因檢驗的知名度- 優劣點
    • 胚胎著床前遺傳基因診斷(PGD)-遺傳基因檢驗市場主要推動材料
    • 全基因譯解-在遺傳基因檢驗的功與過
    • 興起的老年癡呆症患者遺傳基因檢驗的有效性
    • wafarin研究目的遺傳基因檢驗的效用
    • 腫瘤學-遺傳基因檢驗基礎重點領域
    • 遺傳基因檢驗同時也具有助於中樞神經系統疾病治療的可能性
    • 神經退化性疾病-遺傳基因檢驗市場代表性重點領域
    • 老年癡呆症
    • 亨丁頓舞蹈症
    • 遺傳基因檢驗-囊狀纖維化症不可或缺的工具
    • 組織適合性檢驗
    • 次世代定序 - 基因譯解巨大的一步
    • 兒童遺傳基因檢驗讓成人期發病疾病篩檢急速獲得支持
    • 需要改善的全球遺傳基因檢驗產業之安全性規定
    • 面臨的課題
    • 遺傳諮詢 -提升的機會
    • 透過線上的措施
    • 因ACOG (The American congress of obstetricians and gynecologists) 及 ACGM (Advisory Committee on Genetic Modification) 推薦而擴大的囊狀纖維化症檢驗的需求
    • 倫理問題和恰當的法規政策之必要性
    • 肥胖的遺傳基因檢驗相關問題點
    • 妊娠期的診斷和治療-減少梅毒相關的死亡·死產的有效的方法
  • 分子診斷市場 - 考察
    • 急速成長轉向的全球分子診斷
    • 因自動化加速的全球市場
    • 分子診斷-多方面的技術融合所形成
    • 急速發展的傳染病分子診斷市場
    • 人口高齡化,疾病發生-成長基礎的推動要素
    • 視分子診斷市場為自家公司專門領域之醫藥品廠商
    • 訂製針對適當疾病的適當治療
    • 透過第三方機關的有限醫療報酬-障礙
    • 促使臨床結果提升的疾病特定型分子診斷
    • 分子診斷和智慧財產權
    • 不久的將來的商機
    • 醫療訓練及診療行為的課題
    • 對著眼於分子診斷的企業整體而言的障礙
    • 產品行銷 -商業性成功關鍵
    • 合併分子診斷的治療
    • 分子診斷-從集中化轉換到分權化
    • 分子診斷市場競爭環境
    • 其他值得注意的企業和各公司的不同市場區隔競爭地位
    • 著眼於未滿足需求的新加入企業
  • 產品概要
    • 遺傳基因檢驗相關的開場白
    • 遺傳基因檢驗及其使用目的
    • 候補遺傳基因與基因區分
    • 遺傳基因的DNA晶片
    • 遺傳基因變異的檢測所採用的技術
    • 遺傳基因檢驗的種類
    • 產前診斷
    • 癌症篩檢
    • 保原因者檢測
    • 新生兒診察
    • 預測實驗
    • 發病前檢驗
    • 細胞遺傳學檢驗
    • 遺傳基因檢驗流程的階段
    • 規定
    • 風險之外細胞遺傳學檢驗的規定
    • 遺傳基因檢驗的得到好處的醫療機關
    • 藥物遺傳學,藥理基因學
    • 代表性遺傳基因檢驗檢討
    • 囊狀纖維化症
    • 乳癌及卵巢癌症 (BRCA)
    • 老年癡呆症
    • 大腸癌症
    • 血鐵沉著症 (HH)
    • Cowden氏病
    • 亨丁頓舞蹈症
    • 有代表性的檢驗的費用
    • 遺傳基因檢驗的技術
    • 信號放大技術
    • 定量即時PCR分析
    • 非PCR法
    • 其他信號放大技術
    • DNA探針利用產品
  • 產品銷售·技術創新
  • 最新產業趨勢
  • 全球主要加入企業
  • 全球市場預測

第3章 市場

  • 美國
  • 加拿大
  • 日本
  • 歐洲
    • 法國
    • 德國
    • 義大利
    • 英國
    • 其他歐洲各國
  • 亞太地區
  • 其他地區

第4章 競爭環境

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP-1392

This report analyzes the worldwide markets for Genetic Testing in US$ Million by the following Product Segments: Prenatal and Newborn Genetic Testing, Pharmacogenomic Testing, and Predictive Diagnostics. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 86 companies including many key and niche players such as -

Abbott Laboratories
AutoGenomics, Inc.
BioRad Laboratories
ELITech Group S.P.A
PerkinElmer, Inc.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study
    • Prenatal Diagnosis and Newborn Genetic Testing
    • Pharmacogenetics/Pharmacogenomics
    • Predictive Diagnostics

II. EXECUTIVE SUMMARY

1. GLOBAL MARKET OVERVIEW

  • A Curtain Raiser
  • Top Ten Genetic Disorders Worldwide
  • Genetic Testing: Heralding a New Era
  • Genetic Testing Paves the Way for Personalized Medicine
    • Table 1: Drug Ineffectiveness for Select Therapeutic Categories - Necessitating Personalized Medicine (includes corresponding Graph/Chart)
  • Ballooning Global Population Offers Increased Growth Opportunities
    • Table 2: Top 25 Countries Worldwide in Terms of Population: 2007, 2010 & 2015 (As of May'15)
  • Aging Population Drives the Genetic Testing Market
    • Table 3: Global Population Statistics for the 65+ Age Group (2014) (includes corresponding Graph/Chart)
    • Table 4: Elderly Population (60+ Years) as a Percentage of the Total Population (2012 & 2050) (includes corresponding Graph/Chart)
    • Table 5: Life Expectancy at Age 60 and 80 Years - (2010-2015), (2020-2025) & (2045-2050) (includes corresponding Graph/Chart)
    • Table 6: Global Aging Population by Age Group: 1975-2050 (includes corresponding Graph/Chart)
  • Improving Healthcare Expenditure to Drive Demand
    • Table 7: Per-Capita Healthcare Expenditure in Select Regions: 2014 (includes corresponding Graph/Chart)
    • Table 8: Healthcare Spending as a Percentage of GDP by Region: 2014 (includes corresponding Graph/Chart)
  • Genetic Testing - A Critical Part of the Rapidly Developing In-Vitro Diagnostics (IVD) Market
    • Table 9: Global In Vitro Diagnostics (IVD) Market by Geographic Region (2014): Percentage Share Breakdown of Revenues for the United States, Europe, and Rest of World (includes corresponding Graph/Chart)
    • Table 10: Global In-Vitro Diagnostics Market by Sector (2014): Percentage Breakdown of Revenues for Hospital & Commercial Laboratories, and Decentralized & Patient Self-Testing (includes corresponding Graph/Chart)
    • Table 11: Global In-Vitro Diagnostics Market by Segment (2014): Percentage Breakdown of Value Sales for Hematology, Hemostasis, Immunochemistry, Microbiology, Molecular Diagnostics, Point-of-Care Diagnostics, Self-Monitoring Blood Glucose, and Tissue Diagnostics (includes corresponding Graph/Chart)
    • Table 12: Global In Vitro Diagnostics Market by Leading Player (2014): Percentage Share Breakdown of Revenues for Abbott, Biomerieux, Danaher, J&J, Roche, Siemens and Others (includes corresponding Graph/Chart)
  • Genetic Testing: The Rapidly Growing Segment of Molecular Diagnostics Market
    • Table 13: Global Molecular Diagnostics Market (2014): Percentage Breakdown of Market Revenues of Infectious Disease Testing, Genomics, and Blood Donor Screening (includes corresponding Graph/Chart)
  • Biomarker Discovery Leads to Advanced Genetic Testing
  • List of US-FDA Approved Biomarkers for Cancer

2. SEGMENTAL REVIEW

  • Prenatal Testing Market to Rise
  • List of Genetic Disorders by Event, Genetic Manifestation and Prevalence
  • Prenatal Testing - Changing the World of Pregnancy Care
  • Prenatal Testing - A Rudimentary Overview
  • List of Available Prenatal Screening and Diagnostic Tests by Indication
  • Conventional Pre-Natal Diagnostic Techniques - A Risky Affair
    • Other Negativities of Existing Invasive Techniques
    • Emergence of Non-Invasive Prenatal Diagnosis (NIPD)
  • Competition Intensifies in the NIPD Market
    • Commercially Available NIPD (Genetic) Tests for Aneuploidy in the US
  • NIPD Eliminates Risks and Uncertainty of Conventional Diagnostic Procedures
  • Opposition to NIPD Technique - A Significant Hurdle to Adoption
  • Ethical Issues Bog Down Benefits and Proliferation of Prenatal Testing
  • Benefits Outweigh Snags in NIPD Tests
  • Major Factors Influencing Penetration of NIPD Tests
    • Table 14: Price Comparison of Existing Tests and Screening Procedures for Down's Syndrome
  • Diversity in NIPD Usage on the Cards
    • Expanded Newborn Screening
  • Predictive Diagnostics
  • Breast Cancer Gene Testing Market to Expand Strongly
  • Myriad Genetics - The Unquestioned Leader in Breast Cancer Testing
  • Routine Clinical Testing Vs. Predictive Genetic Testing
  • Increasing Incidence and Prevalence of CDDs: A Major Growth Driver
  • Discovery of Novel Biomarkers Crucial to Predictive Diagnostics
  • Unresolved Issues Hamper Widespread Implementation of Genetic Diagnosis and Testing for Monogenetic Disease
  • Dearth of Genetic Counselors - A Major Hurdle for the Predictive Genetic Testing
  • Pharmacogenomics Development Augurs Growth of Genetic Testing Market

3. MARKET TRENDS

  • Direct-to-Consumer Genetic Testing - A Key Trend in the Genetic Testing Market
  • Creating a Platform for New Companies
  • Business Models for DTC Genetic Testing Firms
  • Growing Prominence of DTC Genetic Testing: A Boon or a Curse?
  • Pre-implantation Genetic Diagnosis (PGD) - A Major Driver for the Genetic Testing Market
  • Whole Genome Sequencing - Boon or Bane to Genetic Testing?
  • Validity of Emerging Genetic Tests for Alzheimer's
  • Utility of Genetic Testing for Warfarin Study
  • Oncology - A Key Focus Area for Genetic Testing
    • Table 15: World Cancer Incidence by Geographic Region and Gender (2012): Number of New Cancer Cases Reported (in Thousands) for Asia-Oceania, Europe, North America, Latin America & The Caribbean, and Africa (includes corresponding Graph/Chart)
    • Table 16: New Cancer Cases in the World by Affected Site (2012) (in Thousands) (includes corresponding Graph/Chart)
    • Table 17: Cancer Incidence in Developed Nations By Site: 2012 (includes corresponding Graph/Chart)
    • Table 18: Global Incidence of Common Cancers in Men (2012): Number of New Cases Reported in Thousands for Lung & Bronchus, Prostate, Colorectal, and Liver Cancers (includes corresponding Graph/Chart)
    • Table 19: Global Incidence of Common Cancers in Women (2012): Number of New Cases Reported in Thousands for Breast, Colorectal, Lung & Bronchus, and Liver Cancers (includes corresponding Graph/Chart)
    • Table 20: World Cancer Mortality by Geographic Region and Gender (2012): Number of Cancer-Related Deaths (in Thousands) for Asia-Oceania, Europe, North America, Latin America & The Caribbean, and Africa (includes corresponding Graph/Chart)
  • Genetic Testing May Aid CNS Disease Therapeutics
  • Neurodegenerative Diseases - Major Focus Area for Genetic Testing
  • Alzheimer's Disease
  • Huntington's Disease
  • Genetic Testing - An Indispensible Tool for Cystic Fibrosis
    • Table 21: Most Common Mutations and Worldwide Frequency (includes corresponding Graph/Chart)
  • Histocompatibility Testing
    • Table 22: Global HLA Testing Market (2012-2016E): Revenue Estimates for 2012, 2013, 2014, 2015, and 2016 (includes corresponding Graph/Chart)
  • Next-Generation Sequencing - A Giant Leap in Genome Sequencing
  • Pediatric Genetic Testing for Screening Adult Onset Disorders Fast Gaining Acceptance
  • Better Regulatory Safeguards Required for Global Genetic Testing Industry
  • Challenges Faced
  • Genetic Counseling: Gaining Momentum
  • Online Approach Gains Momentum
  • Recommendations of ACOG and ACGM Augments Demand for Cystic Fibrosis Testing
  • Ethical Issues & Need for Appropriate Regulating Policies
  • Issues Related to Genetic Tests for Obesity
  • Diagnosis and Treatment during Pregnancy - An Effective Way of Alleviating Syphilis Related Deaths and Stillbirths

4. MOLECULAR DIAGNOSTICS MARKET - AN INSIGHT

  • Global Molecular Diagnostics on a High Growth Curve
  • Automation Driving Global Market
  • Molecular Diagnostics: Marking the Convergence of Numerous Technologies
  • MDx Market for Infectious Diseases Zooming Ahead
  • Aging Population, Disease Incidence - Fundamental Drivers of Growth
  • Pharmaceutical Firms Carving Their Niche in Molecular Diagnostics Market
  • Towards Tailoring the Right Treatment for the Right Disease
  • Limited Reimbursements by Third Party Payers - A Stumbling Block
  • Disease-Specific Molecular Diagnostics to Deliver Improved Clinical Outcomes
  • Molecular Diagnostics and Intellectual Property
  • Business Opportunities in the Offing
  • Medical Training and Practice Challenges
  • Hurdles All the Way for Companies Eyeing Molecular Diagnostics
  • Product Marketing - Key to Commercial Success
  • Integration of Molecular Diagnostics into Therapeutics
  • Molecular Diagnostics - Moving from Centralization to Decentralization
  • Competitive Landscape of the Molecular Diagnostics Market
    • Table 23: Leading Players in the Global Molecular Diagnostics Market (2014): Percentage Share Breakdown by Value Sales for Abbott, Becton, Dickinson & Company, bioMerieux, Cepheid, Hologic/Gen-Probe, Novartis, Qiagen, Roche Diagnostics, Siemens and Others (includes corresponding Graph/Chart)
  • Other Noteworthy Companies and their Competitive Position by Segment
  • New Entrants Eye Unmet Needs

5. PRODUCT OVERVIEW

  • Preface to Genetic Testing
  • Genetic Testing and its Applications
  • Gene Candidate and Genome Screen
  • 'DNA Chip' to Chip into Genetic Field
  • Techniques Used to Identify Changes in Genes
  • Types of Genetic Testing
  • Prenatal Diagnosis
  • Cancer Testing
  • Carrier Identification
  • Newborn Screening
  • Predictive Testing
  • Pre-Symptomatic Testing
  • Cytogenetic Tests
  • Steps in Genetic Testing Process
  • Limitations
  • Risks and Other Limitations of Genetic Testing
  • Medical Institutions to Reap the Benefit of Genetic Testing
  • Pharmacogenetics/Pharmacogenomics
  • Review of Select Genetic Tests
  • Cystic Fibrosis
  • Breast and Ovarian Cancer (BRCA)
  • Alzheimer's disease
  • Colorectal Cancer
  • Haemochromatosis (HH)
  • Cowden Syndrome
  • Huntington's disease (HD)
  • Costs of Select Tests
    • Table 24: Costs of Select Genetic Tests
  • Genetic Testing Techniques
  • Signal Amplification Technologies
    • PCR - New Developments
    • Quantitative Real-Time PCR for Molecular Diagnostics
    • Signal Detection and Quantification
    • Quantitative Real-Time RT-PCR Analysis
  • Applications of Quantitative Real-Time PCR Analysis
    • Viral Detection and Viral-Load Monitoring
    • Sensitive Detection of Infectious Disease Agents
    • Predisposition Testing
  • Non-PCR Methods
  • Other Signal Amplification Technologies
  • DNA Probe Based Products
    • Direct Detection of Specific Nucleic Acid Sequences
    • Nucleic Acid Amplification and Detection
    • DNA Sequencing and Gene Detection
    • Arrays of Immobilized Probes (DNA Chips) in Gene Detection
    • RNA Diagnostics

6. PRODUCT LAUNCHES/INNOVATIONS

  • PerkinElmer Launches Genetic Screening Processor® Instruments in China
  • Mayo Clinic Launches Eight NGS Panels for Cardiac Disorders
  • Sequenom Laboratories and Recombine Launch HerediT® UNIVERSAL Test
  • Multipicom NV Launches ADH MASTR™ v2 assay
  • 23andMe Launches Drug Development Unit
  • Quest Diagnostics Launches Neurome™ Exome Sequencing Service
  • Roche Launches cobas 6800/8800 Systems
  • Agena Biosciences Launches MassARRAY 24-Well System
  • FDA Grants Marketing Approval to 23andMe's DTC Bloom Syndrome Carrier Genetic Test
  • Transgenomic to Launch ICE COLD-PCR™ Technology
  • Rosetta Launches Sequencing-based Oncology Tests by Admera Health
  • MedGenome Labs Launches Panorama Prenatal Test
  • Ambry Genetics Launches CVD Genetic Testing Panels
  • Exceltox Launches Pharmacogenomic Testing
  • PerkinElmer Launches SCID Screening Test in North America
  • Quest Diagnostics Introduces BRCAvantage Plus™
  • Genetic Technologies Launches BREVAGenplus Test
  • Sophia Genetics Receives CE-IVD Certification for Genetic Testing
  • Response Genetics Launches Immuno- Oncology Assay
  • DeNA Life Science Launches Mycode Genetic Testing Service
  • Pathway Genomics Launches BRCATrue™ Test
  • Courtagen Launches Genetic Sequencing Tests for Neurodevelopmental Disorders
  • Myriad Genetics Launches EndoPredict® Breast Cancer Test
  • Assurex Health Expands GeneSight® Pharmacogenomic Testing Platform
  • Illumina to Launch VeriSeq Embryo Screening Tool
  • GENEWIZ Launches PGxOne™ Pharmacogenomic Test
  • Ambry Genetics Launches ExomeNext™ and ExomeNext-Rapid™ Genetic Tests
  • Pathway Genomics Launches Genetic Test to Detect Risk of Colorectal Cancer
  • Mount Sinai Laboratory Develops Accurate Genetic Test for SMA
  • Sequenom Launches Non-Invasive Prenatal Test by Laboratoire Cerba
  • CSL Behring Launches Antitrypsin Deficiency Screening Test
  • Interleukin Genetics Launches PerioPredict™
  • US Genomic Health Reports Positive Data from Oncotype DX Prostate Cancer Study
  • Assurex Health Launches GeneSight Test to Predict Folic Acid Conversion and Treat Depression
  • Verifi ® Prenatal Test Available Through California Prenatal Screening Program
  • Children's Mercy Launches TaGSCAN Test
  • General Genetics and Estrogen Gene Test Launch EstroGene™ Test
  • Genetic Analysis Launches GA-map™ Test
  • Myriad Genetics Launches myRisk™ Hereditary Cancer Test
  • GeneDx Launches Genetic Tests for Cancer
  • ArcticDx Launches Vita Risk Pharmacogenetic Test for AMD Patients
  • Quest Diagnostics Launches CYP450 Biomarker- based Diagnostic Test
  • Blueprint Genetics Launches Gene Sequencing Tests
  • Bioiberica Farma Launches Genetic Test for Osteoarthritis
  • Illumina, The Wellcome Trust Centre and the Institute of Cancer Research Roll out Genetic Test
  • Aviir to Launch Genetic Testing for Inherited Cardiovascular Disease
  • Oxford University Hospitals Launches 46-gene Sequencing Test for Cancer

7. RECENT INDUSTRY ACTIVITY

  • ESPERITE Acquires InKaryo
  • Transgenomic Signs Agreement with Exiqon A/S
  • Quest Diagnostics and Myriad Genetics End BRCA Gene Patent Litigation
  • Roche to Acquire Majority Share of Foundation Medicine
  • Roche Acquires Ariosa Diagnostics
  • GSK Collaborates with GE on Oncology Genetic Testing
  • Cancer Genetics to Acquire Gentris Corporation
  • Natera Partners with Mount Sinai Genetic Testing Laboratory
  • Transgenomic to Sell SURVEYOR Nuclease Technology to Integrated DNA Technogies
  • Transgenomic Collaborates with Raptor Pharmaceuticals for Genetic Testing Services
  • AutoGenomic Signs Agreement with Genomas
  • Cancer Genetics Acquires BioServe Biotechnologies
  • PerkinElmer to Close Its Signature Genomics Testing Business
  • LifeLabs Medical Laboratory Services Buys out Centogene's Canadian Business
  • CytoScan Dx Assay by Affymetrix Receives FDA Approval
  • NextGxDx Enters Agreement with PreventionGenetics
  • Neogen Acquires Scidera Genomics
  • Sequenom and CombiMatrix Enter Marketing Agreement for Chromosomal Microarray Analysis
  • Illumina Acquires Verinata Health

8. FOCUS ON SELECT GLOBAL PLAYERS

  • Abbott Laboratories (US)
  • Abbott Molecular, Inc. (US)
  • AutoGenomics, Inc. (US)
  • BioRad Laboratories (US)
  • ELITech Group S.P.A. (France)
  • PerkinElmer, Inc. (US)
  • Quest Diagnostics, Inc. (US)
  • Roche Diagnostics Corp. (Switzerland)
  • Roche Molecular Diagnostics, Inc. (US)
  • Thermo Fisher Scientific (US)
  • Transgenomic, Inc. (US)

9. GLOBAL MARKET PERSPECTIVE

    • Table 25: World Recent Past, Current & Future Analysis for Genetic Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 26: World Historic Review for Genetic Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
    • Table 27: World 14-Year Perspective for Genetic Testing by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • The US: Leading Market for Genetic Testing Globally
    • Demographic Changes Offer Growth Opportunities
    • Table 28: North American Aging Population by Age Group: 1975-2050 (includes corresponding Graph/Chart)
    • Burgeoning Potential for Genetic Testing
    • Predictive Screening: Another Growth Area
    • An important Market for Personalized Medicine
    • Epidemic Proportion of Cancer in the US - Driver for Cancer Genetic Testing
    • Table 29: US Cancer Incidence by Gender (2014): No. of Reported New Cases for Men and Women (includes corresponding Graph/Chart)
    • Table 30: US Incidence of Common Cancers (2014): Number of New Cases Reported by Affected Site (includes corresponding Graph/Chart)
    • Newborn Testing Gains Ground
      • Success Stories
    • Favorable Reimbursement Policies
    • Favorable Insurance Coverage for Cystic Fibrosis Genetic Testing
    • Table 31: CF Carrier Screening: Percentage Breakdown of Population by Coverage Policy: 2012 (includes corresponding Graph/Chart)
    • Table 32: CF Diagnostic Testing: Percentage Breakdown of Population by Coverage Policy: 2012 (includes corresponding Graph/Chart)
    • Popularity of Screening and ACOG Guidelines Sink Invasive Prenatal Diagnosis Numbers
    • Table 33: US Annual Pregnancies by Age Group/Risk Profile: 2010 (includes corresponding Graph/Chart)
    • Tough Market Prospects for Sex Determination Tests
      • Sequenom Bets Big on MaterniT21
    • IP Landscape of NIPD Tests
      • US Patents of cff DNA-based NIPD Tests
    • Direct-to-Consumer Testing - A Growing Market
      • DTC Genetic Tests Provide POCT for Patients in Hospice Care
    • Regulatory Environment
      • Genetic Information Nondiscrimination Act Boosts Genetic Testing
      • NIH Launches Public Database
      • Stricter Regulations for DTC Genetic Testing
    • Product Launches
    • Strategic Corporate Developments
    • Select Key Players
  • B. Market Analytics
    • Table 34: The US Recent Past, Current & Future Analysis for Genetic Testing by Segment - Prenatal and Newborn Genetic Testing, Pharmacogenomic Testing, and Predictive Medicine Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 35: The US Historic Review for Genetic Testing by Segment - Prenatal and Newborn Genetic Testing, Pharmacogenomic Testing, and Predictive Medicine Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
    • Table 36: The US 14-Year Perspective for Genetic Testing by Segment - Percentage Breakdown of Dollar Sales for Prenatal and Newborn Genetic Testing, Pharmacogenomic Testing, and Predictive Medicine Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Regulatory Scenario
    • Rising Incidence of Chronic Diseases Spurs Genetic Testing Demand
    • Table 37: New Cancer Cases in Canada by Gender and Affected Site: 2012 (includes corresponding Graph/Chart)
    • Table 38: New Cancer Cases in Canada by Province: 2012 (includes corresponding Graph/Chart)
    • Table 39: New Cancer Cases in Canada by Age Group and Gender: 2012 (includes corresponding Graph/Chart)
    • Product Launch
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 40: Canadian Recent Past, Current & Future Analysis for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 41: Canadian Historic Review for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Demographics Drive Market Growth
    • Table 42: Japanese Elderly (65+ Years) Population: 2000-2020 (includes corresponding Graph/Chart)
    • DTC Genetic Testing Regulatory Scenario
    • Product Launch
  • B. Market Analytics
    • Table 43: Japanese Recent Past, Current & Future Analysis for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 44: Japanese Historic Review for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Debt Crisis in Europe Affects Healthcare Industry
    • European Healthcare System: In a State of Transition
    • An Insight into Molecular Diagnostics Markets in Europe
    • Cancer Trends
    • Table 45: Cancer Incidence in Europe by Site: 2012 (in Thousands) (includes corresponding Graph/Chart)
    • Aging Population to Drive Demand for Genetic Testing
    • Table 46: Population Breakup by Age Group for Select European Countries: 2013 (as a Percentage of Total Population) (includes corresponding Graph/Chart)
    • European Personalized Medicine Market to Exhibit Robust Growth
    • Legislations/Regulatory Policies in Select European Countries
      • Legislations Governing Genetic Testing in Select European Countries
  • B. Market Analytics
    • Table 47: European Recent Past, Current & Future Analysis for Genetic Testing by Geographic Region - France, Germany, Italy, UK, and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 48: European Historic Review for Genetic Testing by Geographic Region - France, Germany, Italy, UK, and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
    • Table 49: European 14-Year Perspective for Genetic Testing by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, and Rest of Europe Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

4a. FRANCE

  • A. Market Analysis
    • Regulatory Environment in France
    • Product Launch
    • Elitech Group S.P.A. - A Key Player
  • B. Market Analytics
    • Table 50: French Recent Past, Current & Future Analysis for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 51: French Historic Review for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • Parliamentary Regulations
  • B. Market Analytics
    • Table 52: German Recent Past, Current & Future Analysis for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 53: German Historic Review for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)

4c. ITALY

  • Market Analysis
    • Table 54: Italian Recent Past, Current & Future Analysis for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 55: Italian Historic Review for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

  • A. Market Analysis
    • Increased Support for Personalized Medicine to Drive Genetic Testing
    • SMIP for Pharmacogenomic Testing
    • Increasing Need for Less Risky Prenatal Diagnostic Methods in the UK
    • Regulatory Scenario
      • Non-consensual Analysis of DNA Made Illegal
      • Principles for DTC Genetic Testing Laid out by HGC
    • Product Launches
  • B. Market Analytics
    • Table 56: The UK Recent Past, Current & Future Analysis for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 57: The UK Historic Review for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)

4e. REST OF EUROPE

  • A. Market Analysis
    • Product Launches
    • Strategic Corporate Developments
    • Roche Diagnostics Corp. - A Key Player (Switzerland)
  • B. Market Analytics
    • Table 58: Rest of European Recent Past, Current & Future Analysis for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 59: Rest of European Historic Review for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • Healthcare Spending in Asia-Pacific: On the Rise
    • Select Regional Markets
      • China
      • China's FDA Curbs Prenatal Testing
    • Table 60: China - The Most Populous Country Worldwide (July 2013): Total Population (in Millions) by Age Group 0-14 Years, 15-44 Years, 45-64 Years, and 65+ Years for China Vis-a-Vis Other Countries (includes corresponding Graph/Chart)
    • Table 61: China - The Most Populous Country Worldwide (July 2013): Percentage Population by Age Group 0-14 Years, 15-44 Years, 45-64 Years, and 65+ Years for China Vis-a-Vis Other Countries (includes corresponding Graph/Chart)
      • Diagnostics Market in India
      • Australia and New Zealand
      • Approval of Experiments on Human Embryos in New Zealand
      • Singapore Sets Guidelines for Genetic Research and Testing
    • Product Launches
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 62: Asia-Pacific Recent Past, Current & Future Analysis for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 63: Asia-Pacific Historic Review for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)

6. REST OF WORLD

  • Market Analysis
    • Table 64: Rest of World Recent Past, Current & Future Analysis for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 65: Rest of World Historic Review for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Back to Top